Characteristics of patients who sustained or did not sustain remission for 1 year after fulfilling the ADA-free criteria
| Measurement items | Sustained remission (n=25) | Failed remission (n=27) | p Value |
|---|---|---|---|
| Age (years) | 57.1±13.2 | 62.6±8.9 | 0.0833 |
| Disease duration (years) | 6.6±8.4 | 9.8±11.1 | 0.0488* |
| ADA admin periods (weeks) | 59.8±23.7 | 75.6±30.0 | 0.0264* |
| ESR (mm/h) | 11.2±6.3 | 20.2±11.4 | 0.0019** |
| CRP (mg/dL) | 0.09±0.15 | 0.11±0.22 | 0.3289 |
| DAS28-4ESR | 1.7±0.5 | 2.2±0.4 | 0.0010** |
| CDAI | 0.9±1.0 | 1.1±1.6 | 0.7961 |
| SDAI | 1.0±1.0 | 1.2±1.6 | 0.6144 |
| HAQ | 0.18±0.26 | 0.26±0.35 | 0.3531 |
| RF (U/mL) | 58.6±67.3 | 30.9±34.7 | 0.2096 |
| MMP-3 (mg/mL) | 56.0±25.0 | 49.3±31.4 | 0.1129 |
| MTX (mg/w) | 8.1±2.5 | 8.6±2.0 | 0.7645 |
| mTSS | −0.6±1.5 | −0.9±2.0 | 0.5691 |
Data are reported as means± SD, unless otherwise indicated. Statistical significance was assessed by the Wilcoxon rank sum test. *p<0.05, **p<0.01: sustained remission versus failed remission.
ADA administration periods, adalimumab administration periods; CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; mTSS, modified total sharp score; RF, rheumatoid factor; SDAI, simplified disease activity index.